^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Margenza (margetuximab-cmkb) (HER2 inhibitor) + tebotelimab (MGD013) (PD1 inhibitor, LAG-3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms. Add to Collection
Published date:
05/13/2020
Excerpt:
In a cohort of pts with HER2+ tumors treated with MGD013 in combination with margetuximab (investigational anti-HER-2 antibody), 3 PRs have been observed (breast [n=2], colorectal [n=1]; 1 cPR, 2 uPRs) and 2 pts with SD among 6 RE pts.
DOI:
10.1200/JCO.2020.38.15_suppl.3004
Trial ID:
